Assertio Therapeutics Stock News

Assertio Holdings Inc (ASRT) shares closed today 21.6% higher than it did at the end of yesterday. The stock is currently up 21.6% year-to-date, up 85.3% over the past 12 months, and down 26.4% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $2.73 and as low as $1.82 this week.Shares closed 54.3% below its 52-week high and 211.3% above its 52-week low.Trading volume this week was 16.2% lower than the 10-day average and 18.5% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.8. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 559.2% The company's stock price performance over the past 12 months beats the peer average by -1079.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Assertio (ASRT) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that m

Perrigo (NYSE:PRGO) and Assertio (NASDAQ:ASRT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations. Institutional & Insider Ownership 88.7% of Perrigo shares are owned by institutional investors. Comparatively, 19.0% of Assertio shares []

Assertio Holdings Inc. (NASDAQ:ASRT) concluded the trading at $2.10 on Wednesday, December 22 with a fall of -8.70% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $2.30 and 5Y monthly beta was reading 1.55 with its price kept floating in the Assertio Holdings Inc. (ASRT) Is Waiting On The Launchpad To Make A Splash. Read More »

Assertio Holdings Inc. (NASDAQ:ASRT) has a beta value of 1.55 and has seen 1.94 million shares traded in the last trading session. The company, currently valued at $81.53M, closed the last trade at $2.09 per share which meant it gained $0.18 on the day or 9.42% during that session. The ASRT stock price is -177.51% … Assertio Holdings Inc. Is A Buy Small Cap Stock: Analysts Read More »

Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.

During the last session, Assertio Holdings Inc. (NASDAQ:ASRT)s traded shares were 4.17 million, with the beta value of the company hitting 1.54. At the end of the trading day, the stocks price was $1.67, reflecting an intraday gain of 23.70% or $0.32. The 52-week high for the ASRT share is $5.80, that puts it down Assertio Holdings Inc. (NASDAQ: ASRT):The Stock Was Up 49.1 Percent From Its Lows On Thursday, So Whats To Come? Read More »

Antares Pharma Inc (NASDAQ: ATRS ) divested Otrexup (methotrexate) injection to treat rheumatoid arthritis to a subsidiary

Antares Pharma Inc (NASDAQ: ATRS) divested Otrexup (methotrexate) injection to treat rheumatoid arthritis to a subsidiary of Assertio Holdings Inc (NASDAQ: ASRT) for $44 million inclusive of Otrex

EWING, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced the divestiture of OTREXUP ® (methotrexate) injection for the treatment of rheumatoid arthritis to a subsidiary of Assertio Holdings, Inc., a commercial pharmaceutical company, for a total cash consideration of $44.0 million inclusive of OTREXUP ® WIP and finished inventory. Under the terms of the asset purchase agreement, Antares will receive an initial payment of $18.0 million at closing plus two additional time-based payments totalling $26.0 million in 2022.

Trailing 12 Month Reported Revenues of Otrexup Were $15.5 Million

Assertio Holdings, Inc. (NASDAQ:ASRT) saw a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 606,500 shares, a decline of 51.5% from the November 15th total of 1,250,000 shares. Currently, 1.4% of the shares of the company are sold short. Based on an average daily []

The global Peripheral Neuropathy Treatment market is expected a CAGR of 5.8% from 2021 to 2027. Major players are concentrating their efforts on developing drugs to treat peripheral neuropathy, which is expected to drive market growth during the forecast period.

Squarepoint Ops LLC purchased a new stake in Assertio Holdings, Inc. (NASDAQ:ASRT) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 85,484 shares of the companys stock, valued at approximately $133,000. Several other institutional investors and hedge funds have also []

Renaissance Technologies LLC reduced its holdings in shares of Assertio Holdings, Inc. (NASDAQ:ASRT) by 82.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 681,585 shares of the companys stock after selling 3,243,069 shares during the quarter. Renaissance Technologies LLCs holdings in Assertio []